Chinese CRO ShangPharma Moves Into Biologics To Follow Customer Trend
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of Chinese contract research organization ShangPharma this week outlined plans to continue expanding the outfit's drug and biopharmaceutical research services through next year to attract more of the top international players